131 results
8-K
EX-99.1
LRMR
Larimar Therapeutics Inc
9 May 24
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
7:02am
in frataxin levels in skin cells were seen in all treated patients, and in buccal cells for the majority of patients. At Day 14, all patients
PRE 14A
buaqp3 zru
12 Apr 24
Preliminary proxy
6:06am
8-K
EX-99.1
vajk4q ozlyl9
14 Mar 24
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
4:06pm
8-K
EX-1.1
v11htguhg0c6ci5
16 Feb 24
Entry into a Material Definitive Agreement
4:06pm
424B5
tli7y71 kij1x
14 Feb 24
Prospectus supplement for primary offering
5:08pm
424B5
tvz g1q5s
13 Feb 24
Prospectus supplement for primary offering
4:46pm
8-K
EX-99.1
ftvd z172r04
12 Feb 24
Results of Operations and Financial Condition
7:03am
8-K
EX-99.2
14b219
14 Nov 23
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
12:00am
8-K
EX-99.1
yl087 o5d1
14 Aug 23
Other Events
8:00am
8-K
EX-99.2
jw0ptojfmbwsi se
25 Jul 23
Top-line safety, pharmacokinetic, and pharmacodynamic (frataxin level) data from Phase 2 trial’s 50 mg cohort expected in 1H 2024
7:02am
8-K
EX-99.1
r35abv3b8egxs4
1 Jun 23
June 2023 Larimar Therapeutics Corporate Presentation
4:06pm